Capricor Therapeutics, Inc. (CAPR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Capricor Therapeutics, Inc. (CAPR) is up 1.7% since the beginning of the year. At $29 per share, CAPR is trading 27.3% below its 52-week high of $40. Investors who bought $1,000 worth of CAPR shares 5 years ago would now be looking at an investment worth $5,621.

Capricor Therapeutics, Inc. (CAPR) has returned 1.66% so far this year and 255.21% over the past 12 months. Over the last ten years, CAPR has returned -3.48% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Feb 13, 2007, CAPR's average daily return is +0.30%, while the average monthly return is +6.39%. At this rate, an investment would double in approximately 0.9 years.

Historically, 40% of months were positive and 60% were negative. The best month was Apr 2020 with a return of +483.3%, while the worst month was May 2017 at -73.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CAPR closed higher 38% of trading days. The best single day was Dec 3, 2025 with a return of +371.1%, while the worst single day was May 12, 2017 at -62.0%.

Capricor Therapeutics, Inc. has an annualized alpha of 99.47%, beta of 0.63, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 13, 2007.

• This stock participated in 121.24% of S&P 500 Index downside but only 12.40% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.63 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CAPR ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Capricor Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Capricor Therapeutics, Inc. was 99.97%, occurring on Mar 10, 2020. The portfolio has not yet recovered.

The current Capricor Therapeutics, Inc. drawdown is 99.10%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Capricor Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Capricor Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.